Remdisivir superior to standard care for hospitalized adults with COVID-19: Final ACTT-1 results published in NEJM
October 8, 2020
Final results of the Adaptive COVID-19 Treatment Trial (ACTT)-1 investigating remdesivir for the treatment of COVID-19 in hospitalized adults with evidence of lower respiratory tract involvement have been published in the New England Journal of Medicine (NEJM). Of the FHI Clinical study team members, Danielle Fisher, Clinical Research Project Manager, and Wendi McDonald, Associate Project Manager, are listed on the manuscript for their contributions to the study.
